Treatment of glaucoma with Rho Guanine Nucleotide Exchange factor 12 (ARHGEF12) inhibitors
Grant
US12577562B2
Kind: B2
Mar 17, 2026
Assignee
Regeneron Pharmaceuticals, Inc.
Inventors
Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Claudia Schurmann
Abstract
The present disclosure provides methods of treating subjects having glaucoma or elevated intraocular pressure (IOP), methods of identifying subjects having an increased risk of developing glaucoma or developing elevated IOP, methods of detecting human Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) variant nucleic acid molecules and variant polypeptides, and ARHGEF12 variant nucleic acid molecules and variant polypeptides.
CPC Classifications
C12N 15/113
C12N 2310/11
C12N 2310/14
C12N 2310/531
C12N 2310/20
C12N 2320/30
C12N 2320/34
A61P 27/06
C08G 69/10
C12Q 2600/156
C12Q 1/6883
A61K 31/7088
Filing Date
2022-09-28
Application No.
17936244
Claims
8